- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07342608
Sikkerhet og ytelse av LINEA-hjertepacerledningen optimalisert for implantasjon i interventrikulært septum (STARLIGHT)
Sikkerhet og ytelse for LINEA-kardial pacing-elektrode optimalisert for implantasjon i ventrikkelseptum
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Antoine Guihard
- Telefonnummer: +33 1 46 01 33 20
- E-post: antoine.guihard@cf.microport.com
Studiesteder
-
-
-
Ghent, Belgia
- Rekruttering
- Ghent University Hospital
-
Ta kontakt med:
- Jan De Pooter
- E-post: jadpoote.depooter@ugent.be
-
-
-
-
-
Annecy, Frankrike
- Rekruttering
- Centre Hospitalier Annecy Genevois
-
Ta kontakt med:
- Pierre Frey
- E-post: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, Frankrike
- Rekruttering
- CHU Clermont-Ferrand
-
Ta kontakt med:
- Pierre-Antoine Catalan
- E-post: pacatalan@chu-clermontferrand.fr
-
Grenoble, Frankrike
- Rekruttering
- CHU Grenoble
-
Ta kontakt med:
- Adrien Carabelli
- E-post: acarabelli@chu-grenoble.fr
-
Montpellier, Frankrike
- Rekruttering
- Clinique du Millénaire
-
Ta kontakt med:
- Nicolas Clémenty
- E-post: nicolas.clementy@gmail.com
-
Rouen, Frankrike
- Rekruttering
- CHU Rouen Hôpital Charles Nicolle
-
Ta kontakt med:
- Raphaël Al Hamoud
- E-post: raphael.al-hamoud@chu-rouen.fr
-
Tours, Frankrike
- Rekruttering
- Hôpital Trousseau
-
Ta kontakt med:
- Arnaud Bisson
- E-post: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Italia
- Rekruttering
- Ospedale Maggiore della Carità - AO Univ.
-
Ta kontakt med:
- Gabriele Dell'Era
- E-post: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Italia
- Rekruttering
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Ta kontakt med:
- Gianluca Mirizzi
- E-post: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Portugal
- Rekruttering
- ULS de Coimbra
-
Ta kontakt med:
- João Ferreira
- E-post: joaoaferreira29@gmail.com
-
Lisbon, Portugal
- Rekruttering
- ULS Santa Maria
-
Ta kontakt med:
- Nelson Cunha
- E-post: nelsoncunha@campus.ul.pt
-
-
-
-
-
Girona, Spania
- Rekruttering
- Hospital Universitari de Girona Doctor Josep Trueta
-
Ta kontakt med:
- María Emilce Trucco
- E-post: metrucco.girona.ics@gencat.cat
-
Granada, Spania
- Rekruttering
- Hospital Universitario Virgen de las Nieves
-
Ta kontakt med:
- Manuel Molina
- E-post: manuel.molina.lerma@gmail.com
-
Valencia, Spania
- Rekruttering
- Hospital Universitari i Politècnic La Fe
-
Ta kontakt med:
- Óscar Cano
- E-post: oscape13@hotmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LINEA kardiostimulasjonselektrode
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Tidsramme: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Tidsramme: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Tidsramme: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Tidsramme: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Tidsramme: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Tidsramme: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Tidsramme: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Tidsramme: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Tidsramme: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Tidsramme: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LLAI01 - STARLIGHT
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .